Abstract
We describe 2 patients with acute promyelocytic leukemia (APL) in whom torsade de pointes (TdP) developed during treatment with arsenic trioxide. Patient 1 was a 23-year-old woman with second-relapse APL. Ventricular premature beat bigeminy developed on day 27 of treatment, and episodes of TdP developed on day 28. Patient 2 was a 51-year-old woman with second-relapse APL who had cardiomyopathy due to prior anthracycline treatment. TdP developed on day 17 of treatment. Arsenic trioxide is known to cause electrocardiographic abnormalities, such as ventricular tachycardia and prolongation of QT interval. Patient 1 was given fluconazole as a concomitant drug. Patient 2 had cardiomyopathy and hypokalemia. Careful management is needed during arsenic trioxide therapy because this treatment prolongs the QT interval, possibly inducing episodes of TdP.
Similar content being viewed by others
References
Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL), II: clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997;89:3354–3360.
Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341–1348.
Goldsmith S, From AH. Arsenic-induced atypical ventricular tachycardia. N Engl J Med. 1980;303:1096–1098.
Little RE, Kay GN, Cavender JB, Epstein AE, Plumb VJ. Torsade de pointes and T-U wave alternans associated with arsenic poisoning. Pacing Clin Electrophysiol. 1990;13:164–170.
St Petery J, Gross C, Victorica BE. Ventricular fibrillation caused by arsenic poisoning. Am J Dis Child. 1970;120:367–371.
Weinberg SL. The electrocardiogram in acute arsenic poisoning. Am Heart J. 1960;60:971–975.
Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21:3609–3615.
Unnikrishnan D, Dutcher JP, Varshneya N, et al. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide. Blood. 2001;97:1514–1516.
Westervelt P, Brown RA, Adkins DR, et al. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood. 2001;98:266–271.
Ohnishi K, Yoshida H, Shigeno K, et al. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia. Ann Intern Med. 2000;133:881–885.
Ohnishi K, Yoshida H, Shigeno K, et al. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring. Leukemia. 2002;16:617–622.
Drolet B, Simard C, Roden DM. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation. 2004;109:26–29.
Ficker E, Kuryshev YA, Dennis AT, et al. Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol Pharmacol. 2004;66:33–44.
Yamazaki K, Terada H, Naito K, et al. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and electrophysiological study in isolated guinea pig papillary muscles. J Mol Cell Cardiol. 2004;37:268.
Naito K, Kobayashi M, Sahara N, et al. Prognosis of relapsed or refractory patients with acute promyelocytic leukemia treated with arsenic trioxide: comparison between the transplant cases and the non-transplant cases. In: Abstracts of the Japan Society for Hematopoietic Cell Transplantation Conference; December 16–17, 2004; Okayama, Japan. Abstract 159.
Trisenox (arsenic trioxide) injection prescribing information. Seattle, WA: Cell Therapeutics; 2002.
Author information
Authors and Affiliations
About this article
Cite this article
Naito, K., Kobayashi, M., Sahara, N. et al. Two Cases of Acute Promyelocytic Leukemia Complicated by Torsade de Pointes during Arsenic Trioxide Therapy. Int J Hematol 83, 318–323 (2006). https://doi.org/10.1532/IJH97.05056
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.05056